SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
2019 · Molecular Cancer Research · 73 citations
https://doi.org/10.1158/1541-7786.mcr-18-0409
T
Tatsuyuki Chiyoda
Keio University(JP)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
215
Papers
1.5K
Citations
21
h-index
31
i10-index
Tatsuyuki Chiyoda is an academic researcher from Keio University. The author has contributed to research in topics: Ovarian cancer diagnosis and treatment & Endometrial and Cervical Cancer Treatments & Cancer Immunotherapy and Biomarkers. The author has an h-index of 21, co-authored 183 publications.
ORCID: 0000-0002-8214-2242Papers by this author
worksSox21 is a repressor of neuronal differentiation and is antagonized by YB-1
2004 · Neuroscience Letters · 37 citations
https://doi.org/10.1016/j.neulet.2004.01.026
Identification of a novel uterine leiomyoma GWAS locus in a Japanese population
2020 · Scientific Reports · 31 citations
https://doi.org/10.1038/s41598-020-58066-8
Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing
2025 · International Journal of Clinical Oncology · 8 citations
https://doi.org/10.1007/s10147-024-02683-0
Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification
2025 · BJC Reports · 4 citations
https://doi.org/10.1038/s44276-025-00145-2
Transcriptome Concordance Between Borderline Tumors and Endometrioid Carcinoma: An Integrative Genomic Analysis
2025 · Cancer Medicine · 2 citations
https://doi.org/10.1002/cam4.70601
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat